Incretin hormones: Their role in health and disease

Diabetes, Obesity and Metabolism - Tập 20 Số S1 - Trang 5-21 - 2018
Michael A. Nauck1, Juris J. Meier1
1Diabetes Center Bochum-Hattingen, Medical Department I, St. Josef-Hospital, Ruhr-University, Bochum, Germany

Tóm tắt

Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic polypeptide) und GLP‐1 (glucagon‐like peptide‐1) are the known incretin hormones from the upper (GIP, K cells) and lower (GLP‐1, L cells) gut. Together, they are responsible for the incretin effect: a two‐ to three‐fold higher insulin secretory response to oral as compared to intravenous glucose administration. In subjects with type 2 diabetes, this incretin effect is diminished or no longer present. This is the consequence of a substantially reduced effectiveness of GIP on the diabetic endocrine pancreas, and of the negligible physiological role of GLP‐1 in mediating the incretin effect even in healthy subjects. However, the insulinotropic and glucagonostatic effects of GLP‐1 are preserved in subjects with type 2 diabetes to the degree that pharmacological stimulation of GLP‐1 receptors significantly reduces plasma glucose and improves glycaemic control. Thus, it has become a parent compound of incretin‐based glucose‐lowering medications (GLP‐1 receptor agonists and inhibitors of dipeptidyl peptidase‐4 or DPP‐4). GLP‐1, in addition, has multiple effects on various organ systems. Most relevant are a reduction in appetite and food intake, leading to weight loss in the long term. Since GLP‐1 secretion from the gut seems to be impaired in obese subjects, this may even indicate a role in the pathophysiology of obesity. Along these lines, an increased secretion of GLP‐1 induced by delivering nutrients to lower parts of the small intestines (rich in L cells) may be one factor (among others like peptide YY) explaining weight loss and improvements in glycaemic control after bariatric surgery (e.g., Roux‐en‐Y gastric bypass). GIP and GLP‐1, originally characterized as incretin hormones, have additional effects in adipose cells, bone, and the cardiovascular system. Especially, the latter have received attention based on recent findings that GLP‐1 receptor agonists such as liraglutide reduce cardiovascular events and prolong life in high‐risk patients with type 2 diabetes. Thus, incretin hormones have an important role physiologically, namely they are involved in the pathophysiology of obesity and type 2 diabetes, and they have therapeutic potential that can be traced to well‐characterized physiological effects.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(06)69705-5

10.1111/dom.12591

10.1007/BF02427280

10.1016/S2213-8587(15)00482-9

10.1007/BF01225454

10.1007/s00125-007-0598-z

10.1016/S0140-6736(87)91194-9

10.2337/diab.37.2.200

10.1007/978-3-642-81771-7

10.1210/jcem-37-5-826

10.1016/j.cmet.2006.01.004

10.1038/304368a0

10.1111/j.1365-2362.1992.tb01464.x

10.1016/0014-5793(87)81430-8

10.1172/JCI112855

10.1017/S146239940900132X

10.1172/JCI118411

10.1210/endo-128-6-3175

10.1172/JCI116186

10.2337/diab.44.9.1126

10.2337/diabetes.50.3.609

10.1016/j.regpep.2004.06.020

10.1111/j.1749-6632.2000.tb07017.x

10.1210/jcem.87.3.8355

10.1152/ajpendo.00545.2003

10.1007/s00125-003-1103-y

10.1016/0026-0495(94)90164-3

10.1007/s00125-012-2738-3

10.1007/s00125-006-0566-z

10.1053/j.gastro.2005.10.004

10.1210/jc.76.4.912

10.1007/BF01316798

10.1152/ajpendo.1997.273.5.E981

10.1016/S0167-0115(03)00111-3

10.2337/db17-0480

10.1172/JCI119767

10.1007/s11695-008-9759-5

10.1210/jcem-63-2-492

10.1210/jc.2010-2435

10.2337/db15-1541

10.1007/s00125-012-2716-9

10.1016/j.cmet.2017.02.008

10.1038/379069a0

10.1172/JCI990

10.1172/JCI75276

10.1007/s00125-017-4354-8

10.1038/nm.3761

10.1038/nm727

10.2337/diabetes.28.12.1141

10.1172/JCI110335

10.1152/ajpendo.00499.2003

10.1038/nm1196-1254

10.1210/jc.86.9.4382

10.1210/endo.140.1.6421

10.1161/CIRCULATIONAHA.117.028136

10.1161/01.CIR.0000139339.85840.DD

10.1093/eurheartj/ehr309

Fehmann H‐C, 1992, Insulinotropic hormone glucagon‐like peptide‐I(7‐37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma ßTC‐1 cells, Endocrinology, 130, 159, 10.1210/endo.130.1.1309325

10.1038/nm.3997

10.1210/en.2004-0015

10.1016/j.peptides.2012.06.018

10.2337/diabetes.50.7.1562

10.2337/db08-1651

10.1210/jc.2009-1503

10.1210/jc.2010-0841

10.1159/000200956

10.1007/BF01540341

Cheeseman CI, 1996, The effect of GIP and glucagon‐like peptides on intestinal basolateral membrane hexose transport, Am J Physiol (Gastrointest Liver Physiol), 271, G477, 10.1152/ajpgi.1996.271.3.G477

10.1038/oby.2008.393

10.1016/j.bbrc.2010.11.077

Helman CA, 1977, The effect of gastric inhibitory polypeptide on human jejunal water and electrolyte transport, Gastroenterology, 72, 376, 10.1016/S0016-5085(77)80130-3

10.1152/ajpgi.00303.2004

10.1007/s00125-009-1611-5

Meier JJ, 2006, Glucagon‐like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non‐esterified fatty acids in humans, Diabetologia, 1

10.2337/db15-0893

10.1053/j.gastro.2007.09.005

Sancho V, 2007, The action of GLP‐1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients, Int J Mol Med, 19, 961

10.1210/jc.86.3.1229

10.1038/nutd.2016.15

10.1038/ijo.2013.73

10.1152/ajpendo.00418.2014

10.4049/jimmunol.1401149

10.1007/s00125-012-2592-3

10.1074/jbc.M704896200

10.1194/jlr.M006841

10.1016/0167-0115(83)90131-3

10.1007/s00125-015-3651-3

10.2337/db11-1556

10.1007/s00125-016-3896-5

10.4049/jimmunol.1601441

10.1210/me.2005-0187

10.1016/j.bone.2015.01.003

10.1210/en.2007-1292

10.1210/jc.2015-1176

10.1371/journal.pone.0132744

10.1016/j.bone.2015.08.006

10.1359/jbmr.071202

10.1016/j.bone.2016.07.014

10.1210/jc.2014-2547

Garg G, 2016, Glucose‐dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: an association analysis of polymorphisms and bone in young and elderly women, Bone Rep, 4, 23, 10.1016/j.bonr.2015.12.001

10.1016/j.bone.2012.11.039

10.1016/j.bone.2013.07.003

10.1016/j.bone.2007.01.007

10.1210/jc.2013-3766

10.1007/s00223-015-9993-5

10.1111/1753-0407.12102

10.1007/s12020-014-0361-4

10.1152/ajpregu.00003.2015

Egan JM, 2002, Glucagon‐like peptide‐1 augments insulin‐mediated glucose uptake in the obese state, J Clin Endocrinol Metab, 87, 3768, 10.1210/jcem.87.8.8743

10.2337/diacare.26.3.837

10.1210/jc.83.7.2399

10.1210/jc.2003-031403

10.1056/NEJMoa1616011

10.1152/ajpendo.00237.2004

10.1023/A:1026678925120

10.1016/j.regpep.2004.06.018

10.1055/s-2004-826162

10.1016/j.cmet.2016.06.009

10.1210/en.2003-0007

10.1007/BF00429703

RoustLR StesinM GoVLW O'BrienPC RizzaRA ServiceFJ.Role of gastric inhibitory polypeptide in postprandial hyperinsulinemia of Obesity1988:

10.1136/gut.38.6.916

10.2337/db07-1315

10.2337/db14-1751

10.2337/dc13-1283

10.1186/1471-2350-10-19

10.1038/sj.ijo.0801627

10.1016/S1262-3636(09)73458-5

10.1038/ijo.2016.121

10.1152/ajpendo.00471.2015

10.1016/j.molmet.2013.11.010

10.1056/NEJMoa043690

10.1007/s00125-005-1933-x

10.1210/endo.141.12.7806

10.2337/dc06-0392

10.2337/db09-9028

10.1007/s00125-010-1896-4

10.1007/s00125-013-2841-0

10.2337/dc13-0465

10.1007/BF00274255

10.1210/jcem.86.8.7750

10.1016/0026-0495(87)90153-3

10.2337/db10-1332

10.1007/s00125-002-0878-6

10.2337/diabetes.52.2.380

10.1007/BF00401145

10.2337/db07-0100

10.2337/db09-1899

10.1007/BF00581038

10.2337/diabetes.53.9.2397

10.3109/00365528509091657

10.1210/endo-99-3-780

10.1055/s-2007-979067

10.2337/db14-0440

10.2337/diabetes.50.11.2497

10.1055/s-2004-826175

10.1111/j.1464-5491.2008.02579.x

10.1007/s00125-008-1195-5

10.2337/db06-1033

10.1111/dom.12395

10.2337/diabetes.54.8.2436

Thông tin
Thông tin xuất bản

Diabetes, Obesity and Metabolism

Tập 20 Số S1

5-21

Thông tin tác giả